Bharatbook is pleased to announce a new report on "Opportunities in Human Embryonic Stem Cell (hESC) Products" which Overview of Specialty Pharma Companies Developing Embryonic Stem Cell Therapies
Human embryonic stem cells (hESCs) are stem cells derived from the inner cell mass of a blastocyst, which is a stage reached four to five days post-fertilization. Human embryonic stem cells are the most pluripotent of all stem cell types and can develop into over 200 different cell types of the human body.
Human embryonic stem cells were first derived from mouse embryos in 1981 by Martin Evans and Matthew Kaufman, and independently by Gail R. Martin. In 1995, the first successful culturing of embryonic stem cells from non-human primates occurred at the University of Wisconsin-Madison. Another breakthrough followed at the University of Wisconsin-Madison in November 1998 when a group led by Dr. James Thomson developed a technique to isolate and grow hESCs derived from human blastocysts.
Because of their plasticity and unlimited capacity for self-renewal, hESCs have been proposed for use in wide range of applications, including toxicology testing, tissue engineering, cellular therapies, and basic stem cell biology research. However, human embryonic stem cell research is heavily encumbered by patents held by the University of Wisconsin's Wisconsin Alumni Research Foundation (WARF), which creates significant challenges for companies seeking to develop new products.
This market intelligence report explores the complex IP landscape affecting development of human embryonic stem cell products, providing clear guidance for companies entering or already within the market, from collaborating with WARF to less costly alternatives - such as circumventing the claims, conducting research off-shore, and developing embryonic stem cell products for other species.
Key Findings Include:
Trends for hESC Grants, Scientific Publications, and Patents
Market Size Determination for the hESC Product Market
5-Year Market Size Projections (2013-2017)
Embryonic Stem Cell Patent Restrictions and Strategies to Circumvent Claims
Geographical Breakdown (Leading Countries Conducting hESC Research)
Breakdown of Embryonic Stem Cell Research, by Application and Species
Competitive Analysis of hESC Research Supply Vendors
Overview of Specialty Pharma Companies Developing Embryonic Stem Cell Therapies
Overview of Toxicology Testing Legislation (impacting use of hESC in toxicology applications)
Crucial Trends and Unmet Market Needs
And Much More
For more information kindly visit : http://www.bharatbook.com/life-science-market-research-reports/opportunities-in-human-embryonic-stem-cell-hescproducts.html
Related reports: http://www.bharatbook.com/RequestSample.asp?pid=125841
About Bharat Book Bureau:
Bharat Book Bureau is the leading market research information provider for market research reports, , company profiles, industry analysis, country reports , business reports, newsletters and online databases Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. We cover sectors starting from Aeronautics to Zoology.
In case the reports don’t match your requirement then we can do a specialized Custom Research for you. Our multifarious capabilities, cross-sector expertise and detailed knowledge of various markets, put us in a unique position to take up Custom Research demands of yourself.
Contact Us at:
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Call UK: +44 7405 208461
Toll Free No in USA/Canada : 1-866-279-8368
Follow us on twitter: https://twitter.com/researchbook
Follow us on linkedin : http://www.linkedin.com/company/bharat-book-bureau
Our Blog : http://blog.bharatbook.com/
Opportunities in Human Embryonic Stem Cell (hESC) Products